CLINICAL TRIALS PROFILE FOR CORTISONE ACETATE

All Clinical Trials for Cortisone Acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	Alcon Research	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	LuEsther T. Mertz Retinal Research Center	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	Manhattan Eye, Ear & Throat Hospital	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00915343 ↗	Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency	Completed	Shire	Phase 2/Phase 3	2007-08-21	This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency
NCT01771328 ↗	Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia	Unknown status	Haukeland University Hospital	Phase 2	2013-02-01	The conventional glucocorticoid replacement therapy in congenital adrenal hyperplasia (CAH) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This method was recently applied to treat a patient through a critical phase of puberty. This is a clinical trial aiming to evaluate CSHI treatment in patients with CAH. The main objective is to determine the effects of CSHI on metabolic parameters (androstenedione and 17-hydroxyprogesterone profiles, and testosterone,adrenocorticotropic hormone(ACTH), cortisol, and bone markers), and to determine the required glucocorticoid doses. Secondary objectives are to determine effects on clinical status, body weight, blood pressure and other metabolic parameters, as well as on subjective health status (AddiQoL, SF36).
NCT01843530 ↗	Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema	Completed	Technische Universität München	Phase 3	2013-11-01	This trial is a randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema. This study should show that Berinert shortens the time to complete resolution of signs and symptoms of acute ACE-induced angioedema of the upper airway tract compared to placebo when given on top of standard treatment. This study should also compare the time to onset of relief as defined by an at least one point reduction on the severity scale of ACE-induced angioedema with Berinert versus placebo.
NCT01847690 ↗	Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure	Unknown status	Haukeland University Hospital	Phase 2	2013-06-01	The conventional glucocorticoid replacement therapy in primary adrenal insufficiency- Addison's disease,renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Many patients take stress-doses that are extra doses of hydrocortisone or cortisone acetate before or during stressful physical or psychological events. However, the effect of such dosing has not been tested in scientific studies. In this double blind cross-over designed pilot trial we aim to test the effect of an extra dose of cortisol on physical activity and hormone levels.

Clinical Trial Conditions for Cortisone Acetate

Condition Name

Condition Name for Cortisone Acetate
Intervention	Trials
Adrenal Insufficiency	2
Addison Disease	1
Adrenal Hyperplasia, Congenital	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for Cortisone Acetate
Intervention	Trials
Adrenal Insufficiency	2
Adrenogenital Syndrome	1
Spinal Stenosis	1
Adrenocortical Hyperfunction	1

Clinical Trial Locations for Cortisone Acetate

Trials by Country

Trials by Country for Cortisone Acetate
Location	Trials
Norway	2
Germany	1
Netherlands	1
Brazil	1
United States	1

Trials by US State

Trials by US State for Cortisone Acetate
Location	Trials
New York	1

Clinical Trial Progress for Cortisone Acetate

Clinical Trial Phase

Clinical Trial Phase for Cortisone Acetate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Cortisone Acetate
Clinical Trial Phase	Trials
Completed	4
Unknown status	3
Not yet recruiting	1

Clinical Trial Sponsors for Cortisone Acetate

Sponsor Name

Sponsor Name for Cortisone Acetate
Sponsor	Trials
Haukeland University Hospital	2
Technische Universität München	1
Reuth Rehabilitation Hospital	1

Sponsor Type

Sponsor Type for Cortisone Acetate
Sponsor	Trials
Other	12
Industry	2

Cortisone Acetate: Clinical Trials, Market Analysis, and Projections

Introduction to Cortisone Acetate

Cortisone acetate is a steroid hormone widely used for its anti-inflammatory and immunosuppressive properties. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and various endocrine disorders associated with inadequate production of steroid hormones[1].

Clinical Trials and Research

While there is extensive use of cortisone acetate, clinical trials continue to evaluate its efficacy and safety in various conditions.

Hydrocortisone Acetate Clinical Trials

Although the query specifically asks about cortisone acetate, it is worth noting that hydrocortisone acetate, a closely related compound, is also under clinical evaluation. For instance, a Phase 3 study is ongoing to evaluate the safety and efficacy of hydrocortisone acetate suppositories for the treatment of moderate to severe ulcerative colitis. This study involves administering hydrocortisone acetate 90 mg or placebo as a rectal suppository twice a day for 28 days[4].

Implications for Cortisone Acetate

While the specific trial mentioned above is for hydrocortisone acetate, the findings can provide insights into the broader use of corticosteroids like cortisone acetate. These studies help in understanding the optimal dosages, administration routes, and potential side effects, which can be applicable to cortisone acetate as well.

Market Analysis

The market for corticosteroids, including cortisone acetate and hydrocortisone acetate, is significant and growing.

Global Market Size and Growth

The global hydrocortisone acetate market, which can serve as a proxy for understanding the broader corticosteroid market, was estimated to be worth US$ 132.4 million in 2023. It is forecasted to reach US$ 183.1 million by 2030, with a Compound Annual Growth Rate (CAGR) of 4.6% during the forecast period of 2024-2030[2][5].

Market Segmentation

The market is segmented by type, application, and region. Key segments include:

• Type: Injection, tablet, ointment, eye drops, and others.
• Application: Hospital, clinic, and others.
• Region: North America, Europe, Asia Pacific, South America, and Middle East and Africa[2][5].

Key Players

Major pharmaceutical companies such as Pfizer, Novartis, Akorn Pharmaceuticals, Teva Pharmaceuticals, and several others are key players in the hydrocortisone acetate market. These companies are likely to also be significant in the cortisone acetate market due to their extensive experience and resources in corticosteroid production[2][5].

Market Drivers and Trends

Several factors are driving the growth of the corticosteroid market, including:

• Aging Population: An increasing aging population is leading to a higher incidence of age-related diseases that require corticosteroid treatment.
• Rising Awareness of Skin Health: Growing awareness about skin health and the importance of treating skin disorders is boosting the demand for corticosteroids.
• Advancements in Medical Technology: Improvements in medical technology and the development of new formulations and delivery methods are enhancing the efficacy and safety of corticosteroids[2][5].

Challenges and Competitive Landscape

Despite the growth, the market faces several challenges:

• Intense Competition: The market is highly competitive, with numerous players vying for market share. This competition necessitates continuous innovation and improvement in product offerings and marketing strategies.
• Regulatory Scrutiny: Corticosteroids are subject to strict regulatory oversight, and any changes in regulations can impact market dynamics.
• Side Effects and Safety Concerns: Long-term use of corticosteroids can lead to significant side effects, which can affect market growth if not managed properly[1][2].

Projections and Future Outlook

The future outlook for cortisone acetate and similar corticosteroids is positive, driven by the growing demand for effective treatments for inflammatory and immune-related disorders.

• Market Expansion: The market is expected to expand further due to increasing demand and advancements in medical technology.
• Product Innovation: Companies are likely to focus on product innovation, including new formulations and delivery methods, to maintain their competitive edge.
• Geographical Growth: Emerging markets in Asia Pacific, South America, and Africa are expected to contribute significantly to the growth of the corticosteroid market[2][5].

Key Takeaways

• Clinical Trials: Ongoing clinical trials for hydrocortisone acetate provide valuable insights into the use of corticosteroids.
• Market Growth: The global market for corticosteroids is growing, driven by an aging population and rising awareness of skin health.
• Market Segmentation: The market is segmented by type, application, and region, with key players dominating the landscape.
• Challenges: The market faces challenges such as intense competition and regulatory scrutiny.
• Future Outlook: The future outlook is positive, with a focus on product innovation and geographical expansion.

FAQs

What is cortisone acetate used for?

Cortisone acetate is used for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and various endocrine disorders associated with inadequate production of steroid hormones[1].

What are the common side effects of cortisone acetate?

Common side effects include hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, and immune suppression[1].

What is the current market size for hydrocortisone acetate?

The global market for hydrocortisone acetate was estimated to be worth US$ 132.4 million in 2023[5].

What is the projected growth rate for the hydrocortisone acetate market?

The market is forecasted to grow at a CAGR of 4.6% from 2024 to 2030[2][5].

Who are the key players in the hydrocortisone acetate market?

Key players include Pfizer, Novartis, Akorn Pharmaceuticals, Teva Pharmaceuticals, and several others[2][5].

Sources

1. DrugBank: Cortisone acetate: Uses, Interactions, Mechanism of Action.
2. QYResearch: Global Hydrocortisone Acetate Market Insights, Forecast to 2030.
3. Synapse: Cortisone acetate - Drug Targets, Indications, Patents.
4. ClinicalTrials.gov: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories.
5. Valuates Reports: Hydrocortisone Acetate - Market, Report Size, Worth, Revenue.